Archive · 5 Sep 2026
FDA Approves AstraZeneca’s Etcamah for Mutation-Driven Breast Cancer
The U.S. Food and Drug Administration approved a new AstraZeneca cancer medicine called Etcamah.
It is made for some people whose breast cancer has spread and contains a specific mutation.
Doctors must use an approved test to look for that mutation first.
Etcamah works by stopping estrogen from helping cancer cells grow.
AstraZeneca says the medicine delayed cancer progression by more than six months in eligible patients.
An FDA advisory group had earlier said the evidence did not show enough benefit.
The FDA later decided Etcamah could give patients another treatment choice.
AstraZeneca hopes the drug will become a major source of future sales.
The U.S. Food and Drug Administration approved AstraZeneca’s camizestrant, marketed as Etcamah, through its accelerated approval process.
Etcamah can be used with other cancer treatments for metastatic breast cancer patients with a specific mutation linked to disease progression.
Patients must receive an FDA-approved diagnostic test confirming the mutation before taking the therapy.
A prior FDA Oncology Drugs Advisory Committee vote opposed the treatment, citing insufficient evidence of meaningful patient benefit.
AstraZeneca forecasts more than $5 billion in annual Etcamah sales, while analysts project about $2.3 billion by 2032.
- Who
- AstraZeneca and the U.S. Food and Drug Administration; the treatment is intended for eligible patients with metastatic breast cancer.
- What
- The FDA approved AstraZeneca’s camizestrant, to be sold as Etcamah, through the accelerated approval process.
- When
- The approval followed an earlier advisory committee vote against the treatment; the articles do not provide specific dates.
- Where
- The approval applies in the United States.
- Why
- The FDA concluded Etcamah could provide another treatment option for patients with advanced breast cancer carrying the specified mutation.
Evidence Concerns
Approval and Commercial Case
Clinical benefit
Evidence Concerns
The FDA’s Oncology Drugs Advisory Committee voted against Etcamah, saying available evidence did not demonstrate a significant enough benefit for patients.
Approval and Commercial Case
The FDA later concluded that Etcamah could provide another treatment option for women with advanced breast cancer, while AstraZeneca reported a progression delay of more than six months in eligible patients.
Future sales potential
Evidence Concerns
Analysts are more cautious, forecasting approximately $2.3 billion in Etcamah sales by 2032.
Approval and Commercial Case
AstraZeneca expects Etcamah to become a major revenue contributor with potential annual sales exceeding $5 billion.
- Drug
- Camizestrant, marketed under the brand name Etcamah
- Regulator
- U.S. Food and Drug Administration
- Treatment setting
- Used with other cancer treatments for metastatic breast cancer
- Patient selection
- Patients must test positive for a specific mutation linked to disease progression
- Mechanism
- Blocks estrogen from activating cancer cells
- Reported benefit
- AstraZeneca reported that Etcamah can delay disease progression by more than six months in eligible patients
- Sales outlook
- AstraZeneca estimates more than $5 billion in annual sales; analysts forecast about $2.3 billion by 2032